Zhibin Li

TL;DR: A comprehensive quantitative structure-activity relationship (QSAR) study of HDACIs in the hope of identifying the structural determinants for anticancer activity by using various QSAR and classification methods.

TL;DR: The 3D QSAR models built here are very useful in predicting activities of novel compounds for activating PPARγ, which demonstrates that the peroxisome proliferator-activated receptors have increasingly become attractive targets for developing novel anti-type 2 diabetic drugs.

TL;DR: Experiments in vivo showed that compounds 10, 14, and 17 had blood glucose lowering effect in diabetic db/db mouse model after two weeks oral dosing, and strongly support further testing of these lead compounds in other relevant disease animal models to evaluate their potential therapeutic benefits.

TL;DR: In this paper, a patent compound is used as selective regulator of PPAR, particularly used as activator for iso-dipolymers of RXR/PPAR-alpha, RXR / PPAR-gamma, and RXR |PPAR/delta, where circle A, circle B, R1, R2, R3, R4, R5, X, AlK1, Alk2, Ar1, Ar2 are represented as patent specification.

TL;DR: In this paper, the preparation and pharmaceutical use of substituted arylalcanoic acid derivatives of Formula I, wherein ring A, ring B, Rl, R2, R3, R4, R5, X, Alkl, Alk2, Arl, and Ar2 are as defined in the specification.